For Healthcare Professionals

Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease

clipboard-pencil

About the study

A phase 2, double-blind, randomized, placebo-controlled clinical trial to evaluate the safety and efficacy of Allopregnanolone as a regenerative therapeutic for Alzheimer's disease.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

Inclusion Criteria:

  1. Men and postmenopausal women
  2. Age 55 to 80 years old
  3. Meets NIA-AA criteria for probable AD dementia
  4. MMSE of 20-26
  5. APOE ε4 positive
  6. Geriatric Depression Scale short form (GDS-S) score of ≤ 6
  7. No medical contraindications to participation
  8. Capacity to provide informed consent at screening

EXCLUSION CRITERIA

Exclusion Criteria:

  1. Dementia other than probable AD
  2. Use of benzodiazepines, anticonvulsants, antipsychotics, or other drugs that might interact with the GABA-A receptor complex
  3. History of stroke with a modified Hachinski Ischemic Scale score >4
  4. History of seizure disorder, focal brain lesion, traumatic brain injury
  5. History within the last 5 years of a primary or recurrent malignant disease
  6. Unstable or clinically significant cardiovascular, kidney or liver disease
  7. MRI indicative of any other significant abnormality, including but not limited to one or more significant ARIA-E or macro-hemorrhage findings, or multiple microhemorrhages (>8), or Fazekas score of 3; encephalomalacia, aneurysms, vascular malformations, subdural hematoma, or space occupying lesions
  8. Any conditions that would contraindicate MRI studies.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall 520-626-6276Email iconEmail Study Center

Study Details


Contition

Alzheimer Dementia,Late Onset Alzheimer Disease,Neurodegenerative Diseases

Age

55+

Phase

PHASE2

Participants Needed

200

Est. Completion Date

Dec 31, 2026

Treatment Type

INTERVENTIONAL


Sponsor

University of Arizona

ClinicalTrials.gov NCT Identifier

NCT04838301

Study Number

Allo-20-001

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to create a personal profile and 
receive news, resources, and alerts 
about clinical trials related to your conditions of interest.